Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: A non-randomized phase II study

The combination of UFT, etoposide and leucovorin is active in 2nd or 3rd line therapy of Caucasian NSCLC patients and because of its favourable toxicity profile this treatment warrants further investigation.